Two new infusion therapies that target amyloid protein, lecanemab and donanemab, are quietly reshaping what doctors can offer people in the earliest stages of Alzheimer’s disease. In Louisiana, where tens of thousands already live with dementia, specialists say these medicines can slow decline for some patients, but they are neither cures nor simple fixes.
How the treatments work and what they do
Both drugs are monoclonal antibodies that clear beta-amyloid plaques in the brain and, in clinical trials, have shown a modest ability to slow cognitive and functional decline. According to the FDA prescribing information for Leqembi (lecanemab), treatment starts as an IV infusion once every two weeks, with the option to move to once-every-four-weeks maintenance dosing. The FDA prescribing information for Kisunla (donanemab) notes that it is given roughly every four weeks.
The Mayo Clinic reports that these drugs reduce amyloid and slow decline the most in people treated at the earliest stages of disease, but they also carry real risks, including brain swelling and small brain bleeds known collectively as ARIA. In other words, this is not a miracle drip, and careful monitoring is part of the deal.
Why Louisiana is watching
Alzheimer’s groups estimate that about 94,700 people in the state are living with the disease, according to the Alzheimer's Association, and clinicians say Louisiana’s burden is growing. Local neurologists quoted in NOLA.com describe the new infusions as tools, not magic bullets.
'There are no therapies that can regrow neurons or rebuild networks,' Dr. James Rini told the paper, adding that 'I think brain health is the ability to stay engaged.' He warned that Louisiana could see roughly a 20% increase in Alzheimer’s cases over the next five years, a projection that puts even more pressure on early diagnosis and on community supports that help people stay connected and functional for as long as possible.
Who qualifies and what to expect
Both lecanemab and donanemab are indicated for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease, and treatment requires confirmation of amyloid pathology before the first infusion, according to the drug labels. Providers also need to get baseline and periodic MRI scans and often consider ApoE genotyping to better understand a patient’s risk of ARIA.
The Kisunla prescribing information notes that dosing may be stopped once amyloid plaques have been reduced to minimal levels on PET imaging, which means some patients will not stay on the drug indefinitely. For Medicare beneficiaries, the Centers for Medicare & Medicaid Services says coverage is available when clinicians participate in a CMS-facilitated registry and follow the national coverage framework.
Coverage, cost and care gaps in Louisiana
Medicare coverage for these anti-amyloid infusions depends on meeting label criteria and on that registry participation, and patients should expect coinsurance costs, plus additional bills for MRI scans, PET imaging in some cases, and specialist visits, according to CMS. Access in Louisiana is uneven, since infusion centers, PET scanners and memory specialists are clustered in larger cities, leaving many rural and small-town residents facing longer drives and wait lists.
Advocates and state leaders have pushed for stronger local support, including a dementia care specialist program highlighted by the Alzheimer’s Impact Movement and the state chapter. Community programs and primary-care screening remain central to identifying eligible patients and getting them into specialty clinics, while also trying to ease the strain on families who are already doing most of the day-to-day caregiving.
What patients and families should ask
For people worried about memory changes, the first step is a conversation with a clinician about whether formal cognitive testing and an amyloid test are appropriate. That might mean a PET scan, a spinal fluid (CSF) test or, as they become available, certain blood tests. It is also reasonable to ask whether ApoE genetic testing is recommended, what the MRI monitoring schedule would look like and how the registry paperwork would be handled if treatment goes forward.
Patients and families should press for clear explanations of risks and realistic benefits. These drugs can slow decline for some patients, but they do not restore lost brain tissue or reverse Alzheimer’s. It is also worth asking about local resources and care coordination, from support groups to social work services.
Outside of medications, evidence summarized by the Mayo Clinic shows that attention to modifiable risks is still crucial. Controlling blood pressure, treating sleep problems and staying socially and mentally active all support long-term brain health and may help people get more out of whatever treatment plan they choose.
The new infusions are an important medical advance, but in Louisiana the real payoff will depend on early detection, close monitoring and continued investment in specialists, scanners and caregiver supports. Patients and families should expect frank conversations with their neurologist or memory clinic about eligibility, safety monitoring and how these drugs fit into a broader strategy to preserve daily function for as long as possible.
